Dual-target CAR-T cell therapy: latest updates from the 2025 ASH annual meeting
Newer CAR-T designs targeting two cancer markers simultaneously show promise across blood cancers and autoimmune conditions, potentially overcoming limitations of single-target approaches.
A summary of 2025 ASH advances in dual-target CAR-T therapy covering diverse B-cell malignancies, AML, and autoimmune diseases, highlighting logic-gated designs and novel manufacturing platforms to overcome single-target limitations. While published as a letter, this contains substantive clinical trial data references that are not available in other current PubMed-indexed papers.
What the study was
- Study design
- Conference summary/review
- Population
- B-cell malignancies, AML, and autoimmune disease — preclinical and clinical trial data from ASH 2025
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Experimental Hematology & Oncology
Why it surfaced
High-relevance summary of ASH 2025 dual-target CAR-T landscape including clinical phase data; excluded from HIGH because Letter format and no new primary data. Exception applied to inclusion (Letter type) due to clinical content density.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.